US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
'US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026' Report Highlights:
Cancer antibodies have helped the researchers in leaning the entire cancer therapeutics market towards a great transition i.e. from delivering adverse side effects to receiving tons of healthcare benefits such as no adverse side effects or cancer recurrence. Also, availability of prominent designing and research tools in the US have also helped the scientific researchers to design potent cancer-antibody drugs in terms of functionality, quality, and cost. It can be witnessed for the US cancer antibody drug market that the potential impact of the market on US cancer market is far ahead of the clinical implications observed for large base of chemotherapeutics agents and many more.
The extensive and well established base for oncology sector and specifically cancer-antibody drug market has made the US industry share a big percentage to the global development in this respective market, despite of the fact that there are numerous emerging powers in the world. With excessive use of pharmacoeconomics, relaxed formularies as well as e-prescribing market, high number of payers and healthcare policy-makers are also assessing the market towards boosting the research and development platform of the market by adding monotherapy and bispecific therapy to it.
To an extensive level, it is witnessed that the rising volume of research activities and quality of data available in the country have driven the adoption rate of novel drug approvals and grants for research and development platform related with the market. In addition, the primary regulatory body in the country has also made greater use of fast-track methods for making the entire market boomed with breakthroughs and achievements. In the US, technology advancement is also considered as a democratizing force for boosting the market paradigm for cancer-antibody drug market. Biotech and bio-pharmaceutical companies are also inducing patient-centric approaches for turning simple cancer antibody market to a market full of off-to-strategies. In addition, the total spending of medicines in cancer-antibody drug market is expected to increase, thus leading to the adoption of novel wave for innovative and promising products. Some of the prominent factors that will be driving the US cancer antibody drug market are: pricing shifts and emergence and growth of biosimilars. In the respective research report, reported sales, growing trends and opportunities, challenge for future market has been compared, thus providing a realistic idea for the market.
'US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026' Report Highlights:
- US Cancer Antibodies Market Opportunity: > US$ 70 Billion by 2026
- US Cancer Antibodies Market Growth: 100% Absolute Growth Till 2026
- US Cancer Antibodies Market Size Opportunity by Therapeutic Class
- Insight On Clinical Trials by Company, Indication, Patient Segment & Phase
- Insight on FDA Approved 57 Cancer Antibodies Available in US Market
- Price, Dosage, Patent & Sales Insight on Cancer Antibodies Available In Market
- US Cancer Biosimilar Market Opportunity Insight: > US$ 10 Billion by 2026
Cancer antibodies have helped the researchers in leaning the entire cancer therapeutics market towards a great transition i.e. from delivering adverse side effects to receiving tons of healthcare benefits such as no adverse side effects or cancer recurrence. Also, availability of prominent designing and research tools in the US have also helped the scientific researchers to design potent cancer-antibody drugs in terms of functionality, quality, and cost. It can be witnessed for the US cancer antibody drug market that the potential impact of the market on US cancer market is far ahead of the clinical implications observed for large base of chemotherapeutics agents and many more.
The extensive and well established base for oncology sector and specifically cancer-antibody drug market has made the US industry share a big percentage to the global development in this respective market, despite of the fact that there are numerous emerging powers in the world. With excessive use of pharmacoeconomics, relaxed formularies as well as e-prescribing market, high number of payers and healthcare policy-makers are also assessing the market towards boosting the research and development platform of the market by adding monotherapy and bispecific therapy to it.
To an extensive level, it is witnessed that the rising volume of research activities and quality of data available in the country have driven the adoption rate of novel drug approvals and grants for research and development platform related with the market. In addition, the primary regulatory body in the country has also made greater use of fast-track methods for making the entire market boomed with breakthroughs and achievements. In the US, technology advancement is also considered as a democratizing force for boosting the market paradigm for cancer-antibody drug market. Biotech and bio-pharmaceutical companies are also inducing patient-centric approaches for turning simple cancer antibody market to a market full of off-to-strategies. In addition, the total spending of medicines in cancer-antibody drug market is expected to increase, thus leading to the adoption of novel wave for innovative and promising products. Some of the prominent factors that will be driving the US cancer antibody drug market are: pricing shifts and emergence and growth of biosimilars. In the respective research report, reported sales, growing trends and opportunities, challenge for future market has been compared, thus providing a realistic idea for the market.
1. US CANCER ANTIBODIES MARKET ANALYSIS
1.1 Overview
1.2 Current Market Scenario
1.3 US - Leading Cancer Antibodies
2. US CANCER ANTIBODIES MARKET SEGMENTATION BY THERAPEUTIC CLASS
2.1 Immune Checkpoint Inhibitors
2.2 US Bispecific Antibody Market
2.3 US Antibody Drug Conjugate Market
2.4 Other Cancer Antibody Therapeutics
2.4.1 VEGF/VEGFR Inhibiting Antibodies
2.4.2 CD20 Targeting Antibodies
2.4.3 CD38 Targeting Antibodies
2.4.4 EGFR Inhibiting Antibodies
3. US BREAST CANCER ANTIBODIES MARKET
3.1 Current Market Scenario
3.2 Leading Breast Cancer Antibodies
4. US BLOOD CANCER ANTIBODY MARKET
4.1 Current Market Scenario
4.2 Leading Blood Cancer Targeting Antibodies
5. US LUNG CANCER ANTIBODY MARKET
5.1 Current Market Scenario
5.2 Leading Antibodies for Lung Cancer
6. US COLORECTAL CANCER ANTIBODIES MARKET OVERVIEW
7. US CANCER BIOSIMILAR MARKET
7.1 Current Market Scenario
7.2 Market Opportunity & Future Forecast
8. GLOBAL PEPTIDE CANCER THERAPEUTICS CLINICAL TRIALS OVERVIEW
8.1 By Company
8.2 By Indication
8.3 By Patient Segment
8.4 By Phase
9. US HER2 INHIBITING ANTIBODIES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
9.1 Trastuzumab (Herceptin)
9.2 Trastuzumab Biosimilar (Ontruzant)
9.3 Trastuzumab Biosimilar (Ogivri)
9.4 Trastuzumab Biosimilar (Herzuma)
9.5 Trastuzumab Biosimilar (Trazimera)
9.6 Trastuzumab Biosimilar (Kanjinti)
9.7 Trastuzumab & Hyaluronidase Injection (Herceptin Hylecta)
9.8 Pertuzumab (Perjeta)
9.9 Margetuximab (Margenza)
10. US VEGF/VEGFR INHIBITING ANTIBODIES -AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
10.1 Bevacizumab (Avastin)
10.2 Bevacizumab Biosimilar (Mvasi)
10.3 Bevacizumab Biosimilar (Zirabev)
10.4 Ramucirumab (Cyramza)
11. US ANTIBODY-DRUG CONJUGATES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
11.1 Ado-Trastuzumab Emtansine (Kadcyla)
11.2 Fam-Trastuzumab Deruxtecan (Enhertu)
11.3 Trodelvy (Sacituzumab Govitecan-hziy)
11.4 Moxetumomab Pasudotox-tdfk (Lumoxiti)
11.5 Inotuzumab Ozogamicin (Besponsa)
11.6 Gemtuzumab Ozogamicin (Mylotarg)
11.7 Belantamab Mafodotin-blmf (Blenrep)
11.8 Brentuximab Vedotin (Adcetris)
11.9 Polatuzumab Vedotin-piiq (Polivy)
11.10 Enfortumab Vedotin (Padcev)
12. US CD20-DIRECTED ANTIBODY - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
12.1 Rituximab (Mabthera/Rituxan)
12.2 Rituximab Biosimilar (Truxima)
12.3 Rituximab Biosimilar (Riabni)
12.4 Rituximab Biosimilar (Ruxience)
12.5 Rituximab/Hyaluronidase (Rituxan Hycela)
12.6 Obinutuzumab (Gazyva)
12.7 Ofatumumab (Arzerra)
13. US BISPECIFIC ANTIBODIES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
13.1 Blinatumomab (Blincyto)
14. CD52 MONOCLONAL ANTIBODIES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
14.1 Alemtuzumab (Lemtrada)
15. CD38 MONOCLONAL ANTIBODIES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
15.1 Isatuximab-irfc (Sarclisa)
15.2 Darzalex (Daratumumab)
15.3 Darzalex Faspro (Daratumumab/Hyaluronidase)
16. IMMUNE CHECKPOINT INHIBITOR - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
16.1 Pembrolizumab (Keytruda )
16.2 Ipilimumab (Yervoy)
16.3 Nivolumab (Opdivo)
16.4 Durvalumab (Imfinzi) – Urothelial Carcinoma
16.5 Avelumab (Bavencio)
16.6 Atezolizumab (Tecentriq)
16.7 Cemiplimab (Libtayo)
17. EGFR INHIBITORS - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
17.1 Cetuximab (Erbitux)
17.2 Portrazza (Necitumumab)
17.3 Nimotuzumab
17.4 Panitumumab (Vectibix)
18. COMBINATIONAL ANTIBODIES - AVAILABILITY, DOSAGE, PRICE & SALES ANALYSIS
18.1 Trastuzumab, Pertuzumab, & Hyaluronidase (Phesgo)
19. OTHERS CANCER TARGETING ANTIBODIES OF US - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
19.1 Tagraxofusp (Elzonris)
19.2 Tafasitamab (Monjuvi)
19.3 Mogamulizumab-kpkc (Poteligeo)
19.4 Denosumab (Xgeva)
19.5 Empliciti (Elotuzumab)
19.6 Unituxin (dinutuximab) Neuroblastoma
19.7 Satumomab
19.8 Naxitamab-gqgk (Danyelza)
19.9 Iodine I 131 Derlotuximab Biotin
19.10 Capromab Pendetide (ProstaScint)
20. COMPETITIVE LANDSCAPE
20.1 Amgen
20.2 AryoGen Pharmed
20.3 AstraZeneca plc
20.4 BIOCAD
20.5 Boehringer Ingelheim
20.6 Bristol Mayer Squibb
20.7 Daiichi Sankyo Company
20.8 Genentech
20.9 Immunomedics
20.10 Innovent Biologics
20.11 Jassen Pharmaceuticals
20.12 MacroGenics
20.13 mAbxience
20.14 Mylan
20.15 Outlook Therapeutics
20.16 Pfizer
20.17 Prestige Biopharma
20.18 Roche
20.19 Samsung Bio
20.20 Seagen
1.1 Overview
1.2 Current Market Scenario
1.3 US - Leading Cancer Antibodies
2. US CANCER ANTIBODIES MARKET SEGMENTATION BY THERAPEUTIC CLASS
2.1 Immune Checkpoint Inhibitors
2.2 US Bispecific Antibody Market
2.3 US Antibody Drug Conjugate Market
2.4 Other Cancer Antibody Therapeutics
2.4.1 VEGF/VEGFR Inhibiting Antibodies
2.4.2 CD20 Targeting Antibodies
2.4.3 CD38 Targeting Antibodies
2.4.4 EGFR Inhibiting Antibodies
3. US BREAST CANCER ANTIBODIES MARKET
3.1 Current Market Scenario
3.2 Leading Breast Cancer Antibodies
4. US BLOOD CANCER ANTIBODY MARKET
4.1 Current Market Scenario
4.2 Leading Blood Cancer Targeting Antibodies
5. US LUNG CANCER ANTIBODY MARKET
5.1 Current Market Scenario
5.2 Leading Antibodies for Lung Cancer
6. US COLORECTAL CANCER ANTIBODIES MARKET OVERVIEW
7. US CANCER BIOSIMILAR MARKET
7.1 Current Market Scenario
7.2 Market Opportunity & Future Forecast
8. GLOBAL PEPTIDE CANCER THERAPEUTICS CLINICAL TRIALS OVERVIEW
8.1 By Company
8.2 By Indication
8.3 By Patient Segment
8.4 By Phase
9. US HER2 INHIBITING ANTIBODIES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
9.1 Trastuzumab (Herceptin)
9.2 Trastuzumab Biosimilar (Ontruzant)
9.3 Trastuzumab Biosimilar (Ogivri)
9.4 Trastuzumab Biosimilar (Herzuma)
9.5 Trastuzumab Biosimilar (Trazimera)
9.6 Trastuzumab Biosimilar (Kanjinti)
9.7 Trastuzumab & Hyaluronidase Injection (Herceptin Hylecta)
9.8 Pertuzumab (Perjeta)
9.9 Margetuximab (Margenza)
10. US VEGF/VEGFR INHIBITING ANTIBODIES -AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
10.1 Bevacizumab (Avastin)
10.2 Bevacizumab Biosimilar (Mvasi)
10.3 Bevacizumab Biosimilar (Zirabev)
10.4 Ramucirumab (Cyramza)
11. US ANTIBODY-DRUG CONJUGATES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
11.1 Ado-Trastuzumab Emtansine (Kadcyla)
11.2 Fam-Trastuzumab Deruxtecan (Enhertu)
11.3 Trodelvy (Sacituzumab Govitecan-hziy)
11.4 Moxetumomab Pasudotox-tdfk (Lumoxiti)
11.5 Inotuzumab Ozogamicin (Besponsa)
11.6 Gemtuzumab Ozogamicin (Mylotarg)
11.7 Belantamab Mafodotin-blmf (Blenrep)
11.8 Brentuximab Vedotin (Adcetris)
11.9 Polatuzumab Vedotin-piiq (Polivy)
11.10 Enfortumab Vedotin (Padcev)
12. US CD20-DIRECTED ANTIBODY - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
12.1 Rituximab (Mabthera/Rituxan)
12.2 Rituximab Biosimilar (Truxima)
12.3 Rituximab Biosimilar (Riabni)
12.4 Rituximab Biosimilar (Ruxience)
12.5 Rituximab/Hyaluronidase (Rituxan Hycela)
12.6 Obinutuzumab (Gazyva)
12.7 Ofatumumab (Arzerra)
13. US BISPECIFIC ANTIBODIES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
13.1 Blinatumomab (Blincyto)
14. CD52 MONOCLONAL ANTIBODIES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
14.1 Alemtuzumab (Lemtrada)
15. CD38 MONOCLONAL ANTIBODIES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
15.1 Isatuximab-irfc (Sarclisa)
15.2 Darzalex (Daratumumab)
15.3 Darzalex Faspro (Daratumumab/Hyaluronidase)
16. IMMUNE CHECKPOINT INHIBITOR - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
16.1 Pembrolizumab (Keytruda )
16.2 Ipilimumab (Yervoy)
16.3 Nivolumab (Opdivo)
16.4 Durvalumab (Imfinzi) – Urothelial Carcinoma
16.5 Avelumab (Bavencio)
16.6 Atezolizumab (Tecentriq)
16.7 Cemiplimab (Libtayo)
17. EGFR INHIBITORS - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
17.1 Cetuximab (Erbitux)
17.2 Portrazza (Necitumumab)
17.3 Nimotuzumab
17.4 Panitumumab (Vectibix)
18. COMBINATIONAL ANTIBODIES - AVAILABILITY, DOSAGE, PRICE & SALES ANALYSIS
18.1 Trastuzumab, Pertuzumab, & Hyaluronidase (Phesgo)
19. OTHERS CANCER TARGETING ANTIBODIES OF US - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS
19.1 Tagraxofusp (Elzonris)
19.2 Tafasitamab (Monjuvi)
19.3 Mogamulizumab-kpkc (Poteligeo)
19.4 Denosumab (Xgeva)
19.5 Empliciti (Elotuzumab)
19.6 Unituxin (dinutuximab) Neuroblastoma
19.7 Satumomab
19.8 Naxitamab-gqgk (Danyelza)
19.9 Iodine I 131 Derlotuximab Biotin
19.10 Capromab Pendetide (ProstaScint)
20. COMPETITIVE LANDSCAPE
20.1 Amgen
20.2 AryoGen Pharmed
20.3 AstraZeneca plc
20.4 BIOCAD
20.5 Boehringer Ingelheim
20.6 Bristol Mayer Squibb
20.7 Daiichi Sankyo Company
20.8 Genentech
20.9 Immunomedics
20.10 Innovent Biologics
20.11 Jassen Pharmaceuticals
20.12 MacroGenics
20.13 mAbxience
20.14 Mylan
20.15 Outlook Therapeutics
20.16 Pfizer
20.17 Prestige Biopharma
20.18 Roche
20.19 Samsung Bio
20.20 Seagen
LIST OF FIGURES
Figure 1-1: US – Estimated Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030
Figure 1-2: US – Estimated Cancer Deaths, 2020, 2025 & 2030
Figure 1-3: Global – Cancer Antibody Market Opportunity (US$ Billion), 2020 - 2026
Figure 1-4: Global – Cancer Therapeutics Market Opportunity (US$ Billion), 2020 - 2026
Figure 1-5: US – Keytruda Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-6: US - Opdivo Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-7: US - Rituxan Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-8: US - Darzalex Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-9: US - Avastin Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-10: US - Tecentriq Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-11: US - Perjeta Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-12: US - Herceptin Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-13: US - Xgeva Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-14: US - Imfinzi Annual Sales Value (US$ Billion), 2019 & 2020
Figure 2-1: Major Types of Cancer Targeting Antibodies
Figure 2-2: Global – Immune Checkpoint Inhibitors Market by Region (US$ Billion), 2020
Figure 2-3: Global – Immune Checkpoint Inhibitors Market by Region (%), 2020
Figure 2-4: US – Immune Checkpoint Inhibitors Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-5: Global – Immune Checkpoint Inhibitors Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-6: US – Sales Value of Leading Immune Checkpoint Inhibitors (US$ Billion), 2020
Figure 2-7: US – Immune Checkpoint Inhibitors Market Size by Product (%), 2020
Figure 2-8: Global – Bispecific Antibody Market by Region (US$ Million), 2020
Figure 2-9: Global – Bispecific Antibody Market by Region (%), 2020
Figure 2-10: US – Bispecific Antibody Market (US$ Million), 2016-2020
Figure 2-11: US – Bispecific Antibody Market Opportunity (US$ Million), 2020 - 2026
Figure 2-12: Global – Bispecific Antibody Market Opportunity (US$ Million), 2020 - 2026
Figure 2-13: Global – Antibody Drug Conjugate Market by Region (US$ Million), 2020
Figure 2-14: Global – Antibody Drug Conjugate Inhibitors Market by Region (%), 2020
Figure 2-15: US – Antibody Drug Conjugate Inhibitors Market Opportunity (US$ Million), 2020 - 2026
Figure 2-16: Global – Antibody Drug Conjugate Inhibitors Market Opportunity (US$ Million), 2020 - 2026
Figure 2-17: US – Sales Value of Leading Antibody Drug Conjugates (US$ Million), 2020
Figure 2-18: US – Antibody Drug Conjugate Inhibitors Market Size by Product (%), 2020
Figure 2-19: Global – VEGF/VEGFR Inhibitor Antibody Market by Region (US$ Billion), 2020
Figure 2-20: Global – VEGF/VEGFR Inhibitor Antibody Market by Region (%), 2020
Figure 2-21: US – VEGF/VEGFR Inhibitor Antibody Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-22: Global – VEGF/VEGFR Inhibitor Antibody Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-23: US – Sales Value of Leading VEGF/VEGFR Inhibitor Antibodies (US$ Million), 2020
Figure 2-24: US – CD20 Inhibitor Cancer Antibody Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-25: US – Sales Value of Leading CD20 Inhibitor Cancer Antibody (US$ Million), 2020
Figure 2-26: US – Sales Value of Leading CD20 Inhibitor Cancer Antibody (%), 2020
Figure 2-27: US – CD38 Inhibitor Cancer Antibody Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-28: US – Sales Value of Leading CD38 Inhibitor Cancer Antibody (US$ Billion), 2020
Figure 2-29: US – Sales Value of Leading CD38 Inhibitor Cancer Antibody (%), 2020
Figure 3-1: US – Estimated Newly Diagnosed Breast Cancer Cases, 2020, 2025 & 2030
Figure 3-2: US – Estimated Breast Cancer Deaths, 2020, 2025 & 2030
Figure 3-3: US – Sales of Leading Breast Cancer Antibodies (US$ Billion), 2019
Figure 3-4: US – Sales of Leading Breast Cancer Antibodies (US$ Billion), 2020
Figure 4-1: US – Estimated Newly Diagnosed Blood Cancer Cases by Type, 2020
Figure 4-2: US – Estimated Blood Cancer Deaths by Type, 2020
Figure 4-3: US – Sales of Leading Blood Cancer Antibodies (US$ Billion), 2019
Figure 4-4: US – Sales of Leading Blood Cancer Antibodies (US$ Billion), 2020
Figure 5-1: US – Estimated Newly Diagnosed Lung Cancer Cases, 2020, 2025 & 2030
Figure 5-2: US – Estimated Lung Cancer Deaths, 2020, 2025 & 2030
Figure 5-3: US – Sales of Leading Lung Cancer Antibodies (US$ Billion), 2019
Figure 5-4: US – Sales of Leading Lung Cancer Antibodies (US$ Billion), 2020
Figure 6-1: US – Estimated Newly Diagnosed Colon Cancer Cases, 2020, 2025 & 2030
Figure 6-2: US – Estimated Colon Cancer Deaths, 2020, 2025 & 2030
Figure 6-3: US – Estimated Newly Diagnosed Rectum Cancer Cases, 2020, 2025 & 2030
Figure 6-4: US – Estimated Rectum Cancer Deaths, 2020, 2025 & 2030
Figure 6-5: US – Colorectal Cancer Therapeutics Market Opportunity (US$ Billion), 2020 - 2026
Figure 7-1: US – Average Price for 150mg Branded & Biosimilar Trastuzumab (US$), March’2021
Figure 7-2: US – Average Price for 4ml Branded & Biosimilar Bevacizumab (US$), March’2021
Figure 7-3: US – Average Price for 16ml Branded & Biosimilar Bevacizumab (US$), March’2021
Figure 7-4: US – Average Price for 10ml Branded & Biosimilar Rituximab (US$), March’2021
Figure 7-5: US – Average Price for 50ml Branded & Biosimilar Rituximab (US$), March’2021
Figure 7-6: US – Estimated Patent Expiration Year of Cancer Antibodies
Figure 7-7: US – Cancer Biosimilar Antibody Market Size by Product (US$ Million), 2020
Figure 7-8: US – Cancer Biosimilar Antibody Market Size by Product (%), 2020
Figure 7-9: US – Rituxan Biosimilar Market Size by Product (US$ Million), 2020
Figure 7-10: US – Rituxan Market Size by Product (US$ Million), 2020
Figure 7-11: US – Bevacizumab Biosimilar Market Size by Product (US$ Million), 2020
Figure 7-12: US – Bevacizumab Market Size by Product (%), 2020
Figure 7-13: US – Trastuzumab Biosimilar Market Size by Product (US$ Million), 2020
Figure 7-14: US – Trastuzumab Market Size by Product (%), 2020
Figure 7-15: US – Cancer Biosimilar Antibody Market Opportunity (US$ Billion), 2020 - 2026
Figure 7-16: US – Zirabev Market Opportunity (US$ Million), 2020 - 2026
Figure 7-17: US – Mvasi Market Opportunity (US$ Million), 2020 - 2026
Figure 7-18: US – Rituximab Biosimilar Market Opportunity (US$ Million), 2020 - 2026
Figure 7-19: US – Kanjinti Market Opportunity (US$ Million), 2020 - 2026
Figure 7-20: US – Trastuzumab Biosimilar Market Opportunity (US$ Million), 2020 - 2026
Figure 8-1: US - Cancer Antibodies Clinical Pipeline by Company (Number of Drugs), 2021 till 2026
Figure 8-2: US - Cancer Antibodies Clinical Pipeline by Indication (Number of Drugs), 2021 till 2026
Figure 8-3: US - Cancer Antibodies Clinical Pipeline by Patient Segment (Number of Drugs), 2021 till 2026
Figure 8-4: US - Cancer Antibodies Clinical Pipeline by Phase (Number of Drugs), 2021 till 2026
Figure 9-1: Herceptin – Approval Year by Cancer Type
Figure 9-2: Herceptin – Price for a Supply of 10 & Price for Single 150mg Powder for Injection (US$), March’2021
Figure 9-3: Herceptin – Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg), March’2021
Figure 9-4: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Breast Cancer (US$), March’2021
Figure 9-5: Herceptin – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), March’2021
Figure 9-6: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), March’2021
Figure 9-7: US - Herceptin Annual Sales Value (US$/CHF Million), 2017 - 2020
Figure 9-8: US - Herceptin Quarterly Sales Value (US$/CHF Million), 2019
Figure 9-9: US - Herceptin Quarterly Sales Value (US$ Billion), 2020
Figure 9-10: Ontruzant – Price for 150mg & 420mg Powder for Injection (US$), March’2021
Figure 9-11: Ontruzant – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021
Figure 9-12: Ontruzant – Average Cost of Initial Week, Maintenance Week & Annual (US$), March’2021
Figure 9-13: Ontruzant – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), March’2021
Figure 9-14: Ontruzant – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), March’2021
Figure 9-15: Ogivri – Price for 150mg & 420mg Powder for Injection (US$), March’2021
Figure 9-16: Ogivri – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021
Figure 9-17: Ogivri – Average Cost of Initial Week, Maintenance Week & Annual (US$), March’2021
Figure 9-18: Ogivri – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), March’2021
Figure 9-19: Ogivri – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), March’2021
Figure 9-20: Herzuma – Price for 150mg & 420mg Powder for Injection (US$), March’2021
Figure 9-21: Herzuma – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021
Figure 9-22: Herzuma – Average Cost of Initial Week, Maintenance Week & Annual (US$), March’2021
Figure 9-23: Herzuma – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), March’2021
Figure 9-24: Herzuma – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), March’2021
Figure 9-25: Trazimera – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021
Figure 9-26: Trazimera – Average Cost of Initial Week, Maintenance Week & Annual treatment (US$), March’2021
Figure 9-27: Trazimera – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), March’2021
Figure 9-28: Trazimera – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), March’2021
Figure 9-29: Kanjinti – Price for 150mg & 420mg Powder for Injection (US$), March’2021
Figure 9-30: Kanjinti – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021
Figure 9-31: Kanjinti – Average Cost of Initial Week, Maintenance Week & Annual Treatment of Breast Cancer (US$), March’2021
Figure 9-32: Kanjinti – Initial & Maintenance Dose for of Adjuvant Breast Cancer, Gastric Cancer & Esophageal Carcinoma (mg/kg/Week), March’2021
Figure 9-33: Kanjinti – Average Cost of Initial Week, Maintenance Week & Annual Treatment of Adjuvant Breast Cancer, Gastric Cancer & Esophageal Carcinoma (US$), March’2021
Figure 9-34: Herceptin Hylecta – Price for 5ml & Price Per ml of Subcutaneous Solution for Injection (US$), March’2021
Figure 9-35: Herceptin Hylecta – Duration of Single Treatment Cycle & Full Treatment (week), March’2021
Figure 9-36: Perjeta - Approval Year by Cancer Type
Figure 9-37: Perjeta – Patent Expiration Year by Region
Figure 9-38: Perjeta – Price for a Supply of 10 ml and Price Per ml of Intravenous Solution (US$), March’2021
Figure 9-39: Perjeta – Initial & Maintenance Dose for Breast Cancer Treatment (mg/3 weeks), March’2021
Figure 9-40: Perjeta – Minimum & Maximum Treatment Cost for Breast Cancer (US$), March’2021
Figure 9-41: Perjeta – Minimum & Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$), March’2021
Figure 9-42: US - Perjeta Annual Sales Value (US$/CHF Million), 2017 - 2020
Figure 9-43: US - Perjeta Quarterly Sales Value (US$ Billion), 2019
Figure 9-44: US - Perjeta Quarterly Sales Value (US$ Million), 2020
Figure 10-1: Avastin – FDA Approval Year by Indication
Figure 10-2: Avastin – Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$), March’2021
Figure 10-3: Avastin – Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$), March’2021
Figure 10-4: Avastin – Pice for Single Treatment Cycle & Annual Treatment of Breast Cancer (US$), March’2021
Figure 10-5: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), March’2021
Figure 10-6: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), March’2021
Figure 10-7: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks), March’2021
Figure 10-8: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), March’2021
Figure 10-9: US - Avastin Annual Sales Value (US$/CHF Billion), 2017 - 2020
Figure 10-10: US - Avastin Quarterly Sales Value (US$ Billion), 2019
Figure 10-11: US - Avastin Quarterly Sales Value (US$ Million), 2020
Figure 10-12: Mvasi - Price for 4ml Supply & Price Per ml of Intravenous Solution (US$), March’2021
Figure 10-13: Mvasi - Price for 16 ml Supply & Price Per Unit of Intravenous Solution (US$), March’2021
Figure 10-14: Mvasi – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), March’2021
Figure 10-15: Mvasi – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), March’2021
Figure 10-16: Global - Mvasi Annual Sales Value (US$ Million), 2019 & 2020
Figure 10-17: US - Mvasi Annual Sales Value (US$ Million), 2019 & 2020
Figure 10-18: Global - Mvasi Quarterly Sales Value (US$ Million), 2020
Figure 10-19: US - Mvasi Quarterly Sales Value (US$ Million), 2020
Figure 10-20: Zirabev - Price for 4ml Supply & Price Per Unit of Intravenous Solution (US$), March’2021
Figure 10-21: Zirabev - Price for 16 ml Supply & Price Per Unit of Intravenous Solution (US$), March’2021
Figure 10-22: Zirabev – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), March’2021
Figure 10-23: Zirabev – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), March’2021
Figure 10-24: US – Ramucirumab FDA Approval Year by Indication
Figure 10-25: US - Ramucirumab Patent Approval & Expiration Year
Figure 10-26: Cyramza – Cost of Supply of 10ml & Per Unit Cost of Intravenous Solution (US$), March’2021
Figure 10-27: Cyramza – Cost of Supply of 50ml & Per Unit Cost of Intravenous Solution (US$), March’2021
Figure 10-28: Cyramza – Cost of Single Cycle & Annual Treatment Cost for NSCLC (US$)
Figure 10-29: Cyramza – Cost of Single Cycle & Annual Treatment Cost for Gastric, Colorectal & Hepatocellular Carcinoma (US$)
Figure 10-30: Global – Cyramza Annual Sales (US$ Million), 2017-2020
Figure 10-31: US – Cyramza Annual Sales (US$ Million), 2017-2020
Figure 10-32: Cyramza – Annual Sales by Region (US$ Million), 2017-2020
Figure 10-33: Global - Cyramza Annual Sales Value by Region (%), 2020
Figure 10-34: Global – Cyramza Quarterly Sales (US$ Million), 2019 & 2020
Figure 11-1: Kadcyla – FDA Approval Year for Late Stage & Early Stage HER2+ Breast Cancer
Figure 11-2; Kadcyla – Price for Single Unit of 100mg & 160mg Intravenous Powder for Injection (US$), March’2021
Figure 11-3: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 11-4: Kadcyla – Average Cost of Single Treatment Cycle & Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US$), March’2021
Figure 11-5: Kadcyla – Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
Figure 11-6: US - Kadcyla Annual Sales Value (US$/CHF Million), 2017 - 2020
Figure 11-7: US - Kadcyla Quarterly Sales Value (US$ Billion), 2019
Figure 11-8: US - Kadcyla Quarterly Sales Value (US$ Million), 2020
Figure 11-9: Enhertu – FDA Approval Year for Late Stage & Early Stage HER2+ Breast Cancer
Figure 11-10: Enhertu – Cost of Single Supply & Single Treatment Cycle (US$), March’2021
Figure 11-11: Enhertu – Recommended Initial & Reduced Dose (mg/Kg/Cycle), March’2021
Figure 11-12: Enhertu – Cost of Single Treatment Cycle & Annual Treatment of Gastric Cancer (US$), March’2021
Figure 11-13: US - Enhertu Quarterly Sales Value (US$ Million), 2020
Figure 11-14: Trodelvy – FDA Approval & Patent Expiration Year
Figure 11-15: Trodelvy – Average Cost of Single Treatment Cycle & Full Treatment, March’2021
Figure 11-16: US - Trodelvy Quarterly Sales Value (US$ Million), Q2 – Q4, 2020
Figure 11-17: Lumoxiti – Year of Orphan Designation, FDA Approval & Patent Expiration
Figure 11-18: Lumoxiti – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 11-19: Lumoxitin – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), March’2021
Figure 11-20: Besponsa – Duration of Initial Treatment Cycle & Subsequent Cycles (Days)
Figure 11-21; Besponsa – Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m2)
Figure 11-22: Besponsa – Cost of Single Unit & Full Cost of Initial Treatment Cycle (US$), March’2021
Figure 11-23: Besponsa – Cost of Single Unit & Full Cost of Subsequent Treatment Cycle in Patient with CR (US$), March’2021
Figure 11-24: Besponsa – Duration of Treatment of ALL – After & Without HSCT (Weeks)
Figure 11-25: Mylotarg – FDA Approval, Withdrawal & Re-Approval Year
Figure 11-26: Mylotarg – Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
Figure 11-27: Mylotarg – Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), March’2021
Figure 11-28: Mylotarg – Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML
Figure 11-29: Mylotarg – Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)
Figure 11-30: Mylotarg – Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2)
Figure 11-31: Mylotarg – Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US$), March’2021
Figure 11-32: Mylotarg – Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, March’2021
Figure 11-33: Blenrep – Price for 100mg Supply & Price for Single Treatment Cycle (US$), March’2021
Figure 11-34: US - Blenrep Quarter Sales Value (US$/GBP Million), Q3 & Q4, 2020
Figure 11-35: Global - Blenrep Annual Sales Value by Region (US$/GBP Million), 2020
Figure 11-36: Blenrep - US v/s Rest of World Share in Sales Value (%), 2020
Figure 11-37: Adcetris – Patent Issue & Expiration Year
Figure 11-38: Adcetris – Maximum Cost for Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), March’2021
Figure 11-39: Adcetris – Duration for Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)
Figure 11-40: Global - Adcetris Sales Value (US$ Million), 2017 - 2020
Figure 11-41: Polivy – Patent Issue & Expiration Year
Figure 11-42: Polivy – Price for 30mg & 140mg Intravenous Powder for Injection (US$), March’2021
Figure 11-43: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks), March’2021
Figure 11-44: Polivy – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), March’2021
Figure 11-45: US - Polivy Annual Sales Value (US$/CHF Million), 2019 & 2020
Figure 11-46: US - Polivy Quarter Sales Value (US$/CHF Million), Q3 & Q4, 2019
Figure 11-47: US - Polivy Quarter Sales Value (US$/CHF Million), 2020
Figure 11-48: Polivy - US v/s Rest of World Share in Sales Value (%), 2020
Figure 11-49: Padcev – Price for 20mg & 30mg Intravenous Powder for Injection (US$), March’2021
Figure 11-50: Padcev – Average Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), March’2021
Figure 11-51: US - Padcev Annual Sales Value (US$ Million), 2019 - 2020
Figure 11-52: US - Padcev Quarterly Sales Value (US$ Million), 2020
Figure 12-1: Rituxan – FDA Approval Year by Indication
Figure 12-2: Rituxan – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 12-3: Rituxan – Price for a Supply of 50 ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 12-4: Rituxan – Price for a Supply of 100 ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 12-5: Rituxan – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), March’2021
Figure 12-6: Rituxan – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), March’2021
Figure 12-7: US - Rituxan Annual Sales Value (US$/CHF Billion), 2017 - 2020
Figure 12-8: US - Rituxan Quarterly Sales Value (US$ Billion), 2019
Figure 12-9: US - Rituxan Quarterly Sales Value (US$ Million), 2020
Figure 12-10: Rituxan – Annual Sales Value by Region (%), 2020
Figure 12-11: Truxima – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 12-12: Truxima – Price for a Supply of 50 ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 12-13: Truxima – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), March’2021
Figure 12-14: Truxima – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), March’2021
Figure 12-15: Riabni – Cost of Supply of 10ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), March’2021
Figure 12-16: Riabni – Cost of Supply of 50ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), March’2021
Figure 12-17: Riabni – Cost of 8 Cycles, 4 Cycles & Single Cycle for Management of NHL (US$)
Figure 12-18: Ruxience – Cost of Supply of 10ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), March’2021
Figure 12-19: Ruxience – Cost of Supply of 50ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), March’2021
Figure 12-20: Ruxience – Cost of 8 Cycles, 4 Cycles & Single Cycle for Management of NHL (US$)
Figure 12-21: Rituxan Hycela – Price for 11.7 ml Supply & Price Per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US$), March’2021
Figure 12-22: Rituxan Hycela – Price for 13.4 ml Supply & Price Per ml of 26,800 units–1,600 mg/13.4ml Subcutaneous Solution (US$), March’2021
Figure 12-23: Rituxan Hycela –Minimum & Maximum Duration of Follicular lymphoma Treatment (Weeks)
Figure 12-24: Rituxan Hycela – Average Minimum & Maximum Cost of Follicular lymphoma (US$), March’2021
Figure 12-25: Rituxan Hycela – Duration of Single Treatment Cycle & Full Treatment of Previously Untreated Follicular lymphoma (US$)
Figure 12-26: Rituxan Hycela – Average Minimum & Maximum Cost of Previously Untreated Follicular lymphoma (US$), March’2021
Figure 12-27: Rituxan Hycela – Average Minimum & Maximum Cost of Diffuse Large B-Cell Lymphoma (US$), March’2021
Figure 12-28: Rituxan Hycela – Duration of CLL Treatment (Weeks)
Figure 12-29: Rituxan Hycela - Cost of Single Treatment Cycle & Full Treatment of CLL (US$), March’2021
Figure 12-30: Gazyva – Approval Year by Cancer Type
Figure 12-31: Gazyva – Price for 40ml Supply & Price Per ml of Intravenous Solution (US$), March’2021
Figure 12-32: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg), March’2021
Figure 12-33: Gazyva – Duration of Single Treatment Cycle & Full Treatment of CLL (Week), March’2021
Figure 12-34: Gazyva – Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US$), March’2021
Figure 12-35: Gazyva – Minimum & Maximum Duration for Follicular Lymphoma Treatment (Week), March’2021
Figure 12-36: Gazyva – Minimum & Maximum Treatment Cost of Follicular Lymphoma (US$), March’2021
Figure 12-37: Gazyva – Duration of Single Treatment Cycle & Full Treatment Using Monotherapy (Months), March’2021
Figure 12-38: Gazyva – Cost of Single Treatment Cycle & Full Treatment using Monotherapy (US$), March’2021
Figure 12-39: Gazyva – Annual Sales Value (US$/CHF Million), 2017 - 2020
Figure 12-40: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2019
Figure 12-41: Gazyva - US v/s Rest of World Share in Sales Value (%), 2019
Figure 12-42: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2020
Figure 12-43: Gazyva - US v/s Rest of World Share in Sales Value (%), 2020
Figure 12-44: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), March’2021
Figure 12-45: Arzerra – Price for a Supply of 50 ml & Price Per ml of Intravenous Solution (US$), March’2021
Figure 12-46: Arzerra – Initial & Maintenance Dose for Previously Untreated CLL (mg), March’2021
Figure 12-47: Arzerra – Minimum & Maximum Treatment Duration for Previously Untreated CLL (Weeks), March’2021
Figure 12-48: Arzerra – Minimum & Maximum Treatment Cost for Previously Untreated CLL (US$), March’2021
Figure 12-49: Arzerra – Initial & Maintenance Dose for Relapsed CLL (mg), March’2021
Figure 12-50: Arzerra – Minimum & Maximum Treatment Cost for Relapsed CLL (US$), March’2021
Figure 12-51: Arzerra – Initial & Maintenance Dose for Refractory CLL (mg), March’2021
Figure 12-52: Arzerra – Treatment Duration for Refractory CLL (Weeks), March’2021
Figure 12-53: Arzerra – Minimum & Maximum Treatment Cost for Refractory CLL (US$), March’2021
Figure 13-1: Blincyto - Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, March’2021
Figure 13-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , March’2021
Figure 13-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US$), March’2021
Figure 13-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, March’2021
Figure 13-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), March’2021
Figure 13-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), March’2021
Figure 13-7: Blincyto - Cost of Different Treatment Phases for Relapsed B-Cell Precursor ALL (US$), March’2021
Figure 13-8: US - Blincyto Sales Value (US$ Million), 2016 - 2020
Figure 13-9: Blincyto - Quarterly Sales Value (US$ Million), 2019
Figure 13-10: Blincyto - US v/s Rest of World Share in Sales Value (%), 2019
Figure 13-11: US - Blincyto Quarterly Sales Value (US$ Million), 2020
Figure 13-12: Blincyto - US v/s Rest of World Share in Sales Value (%), 2020
Figure 14-1: Lemtrada – Price for 1.2ml Supply & Price Per ml of Intravenous Solution (US$), March’2021
Figure 14-2: Lemtrada – Cost of Single Dose & Single Treatment Cycle (US$), March’2021
Figure 14-3: US - Lemtrada Annual Sales Value (US$/EUR Million), 2018 - 2020
Figure 14-4: US - Lemtrada Quarterly Sales Value (US$/EUR Million), 2020
Figure 14-5: Lemtrada - US v/s Rest of World Share in Sales Value (%), 2020
Figure 15-1: Sarclisa – FDA Approval & Patent Expiration Year
Figure 15-2: Sarclisa – Price for 5 ml Supply & Price Per ml of 20mg/ml Intravenous Solution (US$), March’2021
Figure 15-3: Sarclisa – Price for 25 ml Supply & Price Per ml of 20mg/ml Intravenous Solution (US$), March’2021
Figure 15-4: Sarclisa – Number of Dose Required in Initial & Subsequent Treatment Cycles (Weeks)
Figure 15-5: US - Sarclisa Quarter Sales Value (US$/EUR Million), 2020
Figure 15-6: Global - Sarclisa Annual Sales Value by Region (US$/EUR Million), 2020
Figure 15-7: Sarclisa - US v/s Rest of World Share in Sales Value (%), 2020
Figure 15-8: Darzalex – FDA Approval & Patent Expiration Year
Figure 15-9: Darzalex – Price for 5 ml Supply & Price Per ml of 20mg/ml Intravenous Solution (US$), March’2021
Figure 15-10: Darzalex – Price for 20 ml Supply & Price Per ml of 20mg/ml Intravenous Solution (US$), March’2021
Figure 15-11: Darzalex – Duration of Dose Interval by Treatment Phase (Weeks)
Figure 15-12: US - Darzalex Annual Sales Value (US$ Million), 2017 - 2020
Figure 15-13: Darzalex – Annual Sales by Region (%), 2019
Figure 15-14: US - Darzalex Quarterly Sales Value (US$ Million), 2019
Figure 15-15: US - Darzalex Quarterly Sales Value (US$ Million), 2020
Figure 15-16: Darzalex – Annual Sales by Region (%), 2020
Figure 15-17: Darzalex Faspro – FDA Approval & Patent Expiration Year
Figure 15-18: Darzalex Faspro – Price for 15 ml Supply & Price Per ml of Subcutaneous Solution (US$), March’2021
Figure 15-19: Darzalex Faspro – Duration of Dose Interval by Treatment Phase (Weeks)
Figure 16-1: Keytruda – Patent Expiration Year by Region
Figure 16-2: Keytruda – Price for 4ml & 8ml Supply & Price Per ml of Intravenous Injection (US$), March’2021
Figure 16-3: Keytruda – Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks), March’2021
Figure 16-4: Keytruda - Cost of Single & Full Treatment using Solution of Injection (US$), March’2021
Figure 16-5: Global - Keytruda Annual Sales Value by Region (US$ Billion), 2020
Figure 16-6: Global - Keytruda Annual Sales Value by Region (%), 2020
Figure 16-7: US - Keytruda Annual Sales Value (US$ Billion), 2017 - 2020
Figure 16-8: US - Keytruda Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 16-9: US - Keytruda Quarterly Sales Value (US$ Million), 2020
Figure 16-10: Yervoy – US & Europe Exclusivity Expiration Year
Figure 16-11: Yervoy - Price for 10ml Supply & Price Per ml 5mg/ml Intravenous Injection (US$), March’2021
Figure 16-12: Yervoy – Price for 40ml Supply & Price Per ml 5mg/ml Intravenous Injection (US$), March’2021
Figure 16-13: Yervoy – Duration of Single Treatment Cycle & Full Treatment of Metastatic Melanoma & Hepatocellular Carcinoma (Weeks), March’2021
Figure 16-14: Yervoy – Average Cost of Single Treatment Cycle & Full Treatment of Metastatic Melanoma & Hepatocellular Carcinoma (US$), March’2021
Figure 16-15: Yervoy – Average Cost of Single Treatment Cycle, Initial Year & Remaining Years for Management of Metastatic Melanoma (US$), March’2021
Figure 16-16: Yervoy – Annual Sales Value (US$ Billion), 2016-2020
Figure 16-17: Global - Yervoy Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 16-18: US - Yervoy Quarterly Sales Value (US$ Million), Q1-Q4, 2019
Figure 16-19: Yervoy – US v/s Rest of World Sales Share (%), 2019
Figure 16-20: Global - Yervoy Quarterly Sales Value (US$ Million), Q1-Q4, 2020
Figure 16-21: US - Yervoy Quarterly Sales Value (US$ Million), Q1-Q4, 2020
Figure 16-22: Yervoy – Annual Sales by Region (%), 2020
Figure 16-23: Opdivo – FDA Approval by Indication
Figure 16-24: Opdivo - Patent Expiration Year by Region
Figure 16-25: Opdivo - Price for 4ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), March’2021
Figure 16-26: Opdivo - Price for 10 ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), March’2021
Figure 16-27: Opdivo - Price for 20 ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), March’2021
Figure 16-28: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), March’2021
Figure 16-29: US - Opdivo Annual Sales Value (US$ Million), 2016 - 2020
Figure 16-30: Opdivo – Annual Sales by Region (%), 2019
Figure 16-31: US - Opdivo Quarterly Sales Value (US$ Billion), 2018 & 2019
Figure 16-32: US - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 16-33: Imfinzi – FDA Approval Year by Indication
Figure 16-34: Imfinzi – FDA Approval & Patent Expiration Year
Figure 16-35: Imfinzi – Price for a Supply of 2.4ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 16-36: Imfinzi – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 16-37: Imfinzi - Average Cost of Single Treatment Cycle & Full Treatment of NSCLC (US$), March’2021
Figure 16-38: Global - Imfinzi Annual Sales Value (US$ Million), 2017 - 2020
Figure 16-39: US - Imfinzi Annual Sales Value (US$ Million), 2017 - 2020
Figure 16-40: Imfinzi - Quarterly Sales Value by Region (US$ Million), 2018 & 2019
Figure 16-41: Global - Imfinzi Quarterly Sales Value (US$ Million), 2020
Figure 16-42: US - Imfinzi Quarterly Sales Value US$ Million), 2020
Figure 16-43: Imfinzi – Annual Sales by Region (%), 2020
Figure 16-44: Bavencio – FDA Approval Year by Indication
Figure 16-45: Bavencio - Price for 10ml Supply & Price Per ml of 20mg/ml Intravenous Injection (US$), March’2021
Figure 16-46: Bavencio - Average Cost of Single Treatment Cycle & Annual Treatment (US$), March’2021
Figure 16-47: Bavencio – Annual Sales Value (US$/EUR Million), 2017-2019
Figure 16-48: Bavencio – Quarterly Sales Value (US$ Million), Q1-Q3, 2019 & 2020
Figure 16-49: Tecentriq – FDA Approval Year by Indication
Figure 16-50: Tecentriq - Price for 14ml Supply & Price Per ml of 840mg/14ml Intravenous Injection (US$), March’2021
Figure 16-51: Tecentriq - Price for 20ml Supply & Price Per ml of 1200mg/20ml Intravenous Injection (US$), March’2021
Figure 16-52: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 840mg/2 Week Dose (US$), March’2021
Figure 16-53: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1200mg/3 Week Dose (US$), March’2021
Figure 16-54: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1680mg/4 Week Dose (US$), March’2021
Figure 16-55: US - Tecentriq Annual Sales Value (US$/CHF Million), 2018 - 2020
Figure 16-56: US - Tecentriq Quarterly Sales Value (US$ Million), 2019
Figure 16-57: US - Tecentriq Quarterly Sales Value (US$ Million), 2020
Figure 16-58: Libtayo – FDA Approval Year by Indication
Figure 16-59: Libtayo – Price for a Supply of 7ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 16-60: Libtayo – Cost of Single Treatment Cycle & Annual Treatment Cost (US$), March’2021
Figure 16-61: Global Libtayo Quarterly Sales Value (US$ Million), 2019
Figure 16-62: US - Libtayo Quarterly Sales Value (US$ Million), 2019
Figure 16-63: Libtayo – Annual Sales by Region (%), 2019
Figure 16-64: Libtayo – Quarterly Sales Value (US$ Million), 2020
Figure 16-65: US - Libtayo Quarterly Sales Value (US$ Million), 2020
Figure 16-66: Libtayo – Annual Sales by Region (%), 2020
Figure 17-1: Erbitux - Approval Year by Cancer Type
Figure 17-2: Erbitux - Price for a Supply of 50 ml & Per unit Price of Intravenous Solution (US$), March’2021
Figure 17-3: Erbitux - Price for a Supply of 100 ml & Per unit Price of Intravenous Solution (US$), March’2021
Figure 17-4: Cetuximab – Initial & Maintenance Dose for Colorectal Cancer & Head and Neck Cancer (mg/ m2)
Figure 17-5: Cetuximab – Recommended Dose & Reduced Dose (mg/ m2)
Figure 17-6: Global – Erbitux Annual Sales (US$ Million), 2017-2019
Figure 17-7: Cetuximab - Annual Sales by Region (US$ Million), 2018 & 2019
Figure 17-8: Cetuximab - Annual Sales by Region (%), 2019
Figure 17-9: US – Necitumumab FDA Approval & Patent Exclusivity Year
Figure 17-10: Portrazza - Price for 50ml Supply & Price per unit of 16mg Intravenous Solution (US$), March’2021
Figure 17-11: Portrazza – Minimum Dose & Maximum Dose (in mg)
Figure 17-12: Vectibix - FDA Approval & Patent Expiration Year
Figure 17-13: Vectibix – Price for a Supply of 5 ml & Price Per ml of Intravenous Solution (US$), March’2021
Figure 17-14: Vectibix – Price for a Supply of 20 ml & Price Per ml of Intravenous Solution (US$), March’2021
Figure 17-15: Vectibix – Cost of Single Treatment Cycle & Annual Treatment Cost for Colorectal Cancer (US$), March’2021
Figure 17-16: Global - Vectibix Annual Sales Value (US$ Million), 2015 - 2020
Figure 17-17: US - Vectibix Annual Sales Value (US$ Million), 2018 - 2020
Figure 17-18: Vectibix - Sales Share US v/s Rest of World (%), 2019
Figure 17-19: Global – Vectibix Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 17-20: Vectibix – Quarterly Sales Value by Region (US$ Million), 2020
Figure 17-21: Vectibix – Annual Sales Value (%) by Region, 2020
Figure 18-1: Phesgo – Price for various Supplies of Subcutaneous Solution for Injection (US$), March’2021
Figure 18-2: Phesgo – Duration of Treatment by Type (Cycles), March’2021
Figure 19-1: ELZONRIS – Average Cost for Single Treatment Cycle & Annual Treatment Cost (US$), March’2021
Figure 19-2: US - Elzonris Quarterly Sales Value (US$ Million), 2019
Figure 19-3: Monjuvi – Number of Dose per Treatment Cycle by Phase
Figure 19-4: Monjuvi – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 19-5: Monjuvi – Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), March’2021
Figure 19-6: US - Monjuvi Quarterly Sales Value (US$ Million), Q3 & Q4, 2020
Figure 19-7: Poteligeo – FDA Approval & Patent Expiration Year
Figure 19-8: Poteligeo – Price for 5ml Supply & Price Per Unit of 4mg/l Intravenous Solution (US$), March’2021
Figure 19-9: Poteligeo – Number of Dose Administration in Initial & Subsequent Treatment Cycle
Figure 19-10: Poteligeo – Cost of Single Dose, Initial & Subsequent Treatment Cycle (US$), March’2021
Figure 19-11: Global - Poteligeo Sales Value (US$ Million), 2018 - 2020
Figure 19-12: Xgeva – Cost of Supply of 1.7ml & Per Unit Price of 120mg Solution (US$), March’2021
Figure 19-13: Xgeva – Cost of Single Cycle & Annual Cost of Treatment in Multiple Myeloma (US$)
Figure 19-14: Global – Xgeva Annual Sales (US$ Million), 2017-2020
Figure 19-15: Xgeva - Annual Sales by Region (US$ Million), 2019
Figure 19-16: Xgeva - Annual Sales by Region (%), 2019
Figure 19-17: Xgeva - Quarterely Sales by Region (US$ Million), 2019
Figure 19-18: Global – Xgeva Quarterely Sales (US$ Million), 2020
Figure 19-19: US – Xgeva Quarterely Sales (US$ Million), 2020
Figure 19-20: Xgeva - Annual Sales by Region (%), 2020
Figure 19-21: Empliciti – Patent Issue & Expiration Year
Figure 19-22: Empliciti – Price for 300mg & 400mg Supply of Intravenous Powder for Injection (US$), March’2021
Figure 19-23: Empliciti – Number of Dose Administration During Initial 2 Cycles & Subsequent Cycles
Figure 19-24: Empliciti – Cost of Single Cycle During Initial 2 Cycles & Subsequent Cycles (US$), March’2021
Figure 19-25: US - Empliciti Annual Sales Value (US$ Million), 2017 - 2020
Figure 19-26: Empliciti – Annual Sales by Region (%), 2019
Figure 19-27: US - Empliciti Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 19-28: US - Empliciti Quarterly Sales Value (US$ Million), 2020
Figure 19-29: Empliciti – Annual Sales by Region (%), 2020
Figure 19-30: US – Unituxin FDA Approval & Patent Exclusivity Year
Figure 19-31: Unituxin – Cost of Supply of 5ml & Per Unit Cost of Intravenous Solution (US$), March’2021
Figure 19-32: Unituxin – Cost of Single Cycle & Full Treatment Cost (US$)
Figure 19-33: Global – Unituxin Annual Sales (US$ Million), 2017-2020
Figure 19-34: Global – Unituxin Quarterely Sales (US$ Million), 2020
Figure 19-35: Naxitamab – Cost of Supply of 10ml & Per Unit Cost of Intravenous Solution (US$), March’2021
Figure 1-1: US – Estimated Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030
Figure 1-2: US – Estimated Cancer Deaths, 2020, 2025 & 2030
Figure 1-3: Global – Cancer Antibody Market Opportunity (US$ Billion), 2020 - 2026
Figure 1-4: Global – Cancer Therapeutics Market Opportunity (US$ Billion), 2020 - 2026
Figure 1-5: US – Keytruda Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-6: US - Opdivo Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-7: US - Rituxan Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-8: US - Darzalex Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-9: US - Avastin Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-10: US - Tecentriq Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-11: US - Perjeta Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-12: US - Herceptin Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-13: US - Xgeva Annual Sales Value (US$ Billion), 2019 & 2020
Figure 1-14: US - Imfinzi Annual Sales Value (US$ Billion), 2019 & 2020
Figure 2-1: Major Types of Cancer Targeting Antibodies
Figure 2-2: Global – Immune Checkpoint Inhibitors Market by Region (US$ Billion), 2020
Figure 2-3: Global – Immune Checkpoint Inhibitors Market by Region (%), 2020
Figure 2-4: US – Immune Checkpoint Inhibitors Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-5: Global – Immune Checkpoint Inhibitors Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-6: US – Sales Value of Leading Immune Checkpoint Inhibitors (US$ Billion), 2020
Figure 2-7: US – Immune Checkpoint Inhibitors Market Size by Product (%), 2020
Figure 2-8: Global – Bispecific Antibody Market by Region (US$ Million), 2020
Figure 2-9: Global – Bispecific Antibody Market by Region (%), 2020
Figure 2-10: US – Bispecific Antibody Market (US$ Million), 2016-2020
Figure 2-11: US – Bispecific Antibody Market Opportunity (US$ Million), 2020 - 2026
Figure 2-12: Global – Bispecific Antibody Market Opportunity (US$ Million), 2020 - 2026
Figure 2-13: Global – Antibody Drug Conjugate Market by Region (US$ Million), 2020
Figure 2-14: Global – Antibody Drug Conjugate Inhibitors Market by Region (%), 2020
Figure 2-15: US – Antibody Drug Conjugate Inhibitors Market Opportunity (US$ Million), 2020 - 2026
Figure 2-16: Global – Antibody Drug Conjugate Inhibitors Market Opportunity (US$ Million), 2020 - 2026
Figure 2-17: US – Sales Value of Leading Antibody Drug Conjugates (US$ Million), 2020
Figure 2-18: US – Antibody Drug Conjugate Inhibitors Market Size by Product (%), 2020
Figure 2-19: Global – VEGF/VEGFR Inhibitor Antibody Market by Region (US$ Billion), 2020
Figure 2-20: Global – VEGF/VEGFR Inhibitor Antibody Market by Region (%), 2020
Figure 2-21: US – VEGF/VEGFR Inhibitor Antibody Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-22: Global – VEGF/VEGFR Inhibitor Antibody Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-23: US – Sales Value of Leading VEGF/VEGFR Inhibitor Antibodies (US$ Million), 2020
Figure 2-24: US – CD20 Inhibitor Cancer Antibody Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-25: US – Sales Value of Leading CD20 Inhibitor Cancer Antibody (US$ Million), 2020
Figure 2-26: US – Sales Value of Leading CD20 Inhibitor Cancer Antibody (%), 2020
Figure 2-27: US – CD38 Inhibitor Cancer Antibody Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-28: US – Sales Value of Leading CD38 Inhibitor Cancer Antibody (US$ Billion), 2020
Figure 2-29: US – Sales Value of Leading CD38 Inhibitor Cancer Antibody (%), 2020
Figure 3-1: US – Estimated Newly Diagnosed Breast Cancer Cases, 2020, 2025 & 2030
Figure 3-2: US – Estimated Breast Cancer Deaths, 2020, 2025 & 2030
Figure 3-3: US – Sales of Leading Breast Cancer Antibodies (US$ Billion), 2019
Figure 3-4: US – Sales of Leading Breast Cancer Antibodies (US$ Billion), 2020
Figure 4-1: US – Estimated Newly Diagnosed Blood Cancer Cases by Type, 2020
Figure 4-2: US – Estimated Blood Cancer Deaths by Type, 2020
Figure 4-3: US – Sales of Leading Blood Cancer Antibodies (US$ Billion), 2019
Figure 4-4: US – Sales of Leading Blood Cancer Antibodies (US$ Billion), 2020
Figure 5-1: US – Estimated Newly Diagnosed Lung Cancer Cases, 2020, 2025 & 2030
Figure 5-2: US – Estimated Lung Cancer Deaths, 2020, 2025 & 2030
Figure 5-3: US – Sales of Leading Lung Cancer Antibodies (US$ Billion), 2019
Figure 5-4: US – Sales of Leading Lung Cancer Antibodies (US$ Billion), 2020
Figure 6-1: US – Estimated Newly Diagnosed Colon Cancer Cases, 2020, 2025 & 2030
Figure 6-2: US – Estimated Colon Cancer Deaths, 2020, 2025 & 2030
Figure 6-3: US – Estimated Newly Diagnosed Rectum Cancer Cases, 2020, 2025 & 2030
Figure 6-4: US – Estimated Rectum Cancer Deaths, 2020, 2025 & 2030
Figure 6-5: US – Colorectal Cancer Therapeutics Market Opportunity (US$ Billion), 2020 - 2026
Figure 7-1: US – Average Price for 150mg Branded & Biosimilar Trastuzumab (US$), March’2021
Figure 7-2: US – Average Price for 4ml Branded & Biosimilar Bevacizumab (US$), March’2021
Figure 7-3: US – Average Price for 16ml Branded & Biosimilar Bevacizumab (US$), March’2021
Figure 7-4: US – Average Price for 10ml Branded & Biosimilar Rituximab (US$), March’2021
Figure 7-5: US – Average Price for 50ml Branded & Biosimilar Rituximab (US$), March’2021
Figure 7-6: US – Estimated Patent Expiration Year of Cancer Antibodies
Figure 7-7: US – Cancer Biosimilar Antibody Market Size by Product (US$ Million), 2020
Figure 7-8: US – Cancer Biosimilar Antibody Market Size by Product (%), 2020
Figure 7-9: US – Rituxan Biosimilar Market Size by Product (US$ Million), 2020
Figure 7-10: US – Rituxan Market Size by Product (US$ Million), 2020
Figure 7-11: US – Bevacizumab Biosimilar Market Size by Product (US$ Million), 2020
Figure 7-12: US – Bevacizumab Market Size by Product (%), 2020
Figure 7-13: US – Trastuzumab Biosimilar Market Size by Product (US$ Million), 2020
Figure 7-14: US – Trastuzumab Market Size by Product (%), 2020
Figure 7-15: US – Cancer Biosimilar Antibody Market Opportunity (US$ Billion), 2020 - 2026
Figure 7-16: US – Zirabev Market Opportunity (US$ Million), 2020 - 2026
Figure 7-17: US – Mvasi Market Opportunity (US$ Million), 2020 - 2026
Figure 7-18: US – Rituximab Biosimilar Market Opportunity (US$ Million), 2020 - 2026
Figure 7-19: US – Kanjinti Market Opportunity (US$ Million), 2020 - 2026
Figure 7-20: US – Trastuzumab Biosimilar Market Opportunity (US$ Million), 2020 - 2026
Figure 8-1: US - Cancer Antibodies Clinical Pipeline by Company (Number of Drugs), 2021 till 2026
Figure 8-2: US - Cancer Antibodies Clinical Pipeline by Indication (Number of Drugs), 2021 till 2026
Figure 8-3: US - Cancer Antibodies Clinical Pipeline by Patient Segment (Number of Drugs), 2021 till 2026
Figure 8-4: US - Cancer Antibodies Clinical Pipeline by Phase (Number of Drugs), 2021 till 2026
Figure 9-1: Herceptin – Approval Year by Cancer Type
Figure 9-2: Herceptin – Price for a Supply of 10 & Price for Single 150mg Powder for Injection (US$), March’2021
Figure 9-3: Herceptin – Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg), March’2021
Figure 9-4: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Breast Cancer (US$), March’2021
Figure 9-5: Herceptin – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), March’2021
Figure 9-6: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), March’2021
Figure 9-7: US - Herceptin Annual Sales Value (US$/CHF Million), 2017 - 2020
Figure 9-8: US - Herceptin Quarterly Sales Value (US$/CHF Million), 2019
Figure 9-9: US - Herceptin Quarterly Sales Value (US$ Billion), 2020
Figure 9-10: Ontruzant – Price for 150mg & 420mg Powder for Injection (US$), March’2021
Figure 9-11: Ontruzant – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021
Figure 9-12: Ontruzant – Average Cost of Initial Week, Maintenance Week & Annual (US$), March’2021
Figure 9-13: Ontruzant – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), March’2021
Figure 9-14: Ontruzant – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), March’2021
Figure 9-15: Ogivri – Price for 150mg & 420mg Powder for Injection (US$), March’2021
Figure 9-16: Ogivri – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021
Figure 9-17: Ogivri – Average Cost of Initial Week, Maintenance Week & Annual (US$), March’2021
Figure 9-18: Ogivri – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), March’2021
Figure 9-19: Ogivri – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), March’2021
Figure 9-20: Herzuma – Price for 150mg & 420mg Powder for Injection (US$), March’2021
Figure 9-21: Herzuma – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021
Figure 9-22: Herzuma – Average Cost of Initial Week, Maintenance Week & Annual (US$), March’2021
Figure 9-23: Herzuma – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), March’2021
Figure 9-24: Herzuma – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), March’2021
Figure 9-25: Trazimera – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021
Figure 9-26: Trazimera – Average Cost of Initial Week, Maintenance Week & Annual treatment (US$), March’2021
Figure 9-27: Trazimera – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), March’2021
Figure 9-28: Trazimera – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), March’2021
Figure 9-29: Kanjinti – Price for 150mg & 420mg Powder for Injection (US$), March’2021
Figure 9-30: Kanjinti – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021
Figure 9-31: Kanjinti – Average Cost of Initial Week, Maintenance Week & Annual Treatment of Breast Cancer (US$), March’2021
Figure 9-32: Kanjinti – Initial & Maintenance Dose for of Adjuvant Breast Cancer, Gastric Cancer & Esophageal Carcinoma (mg/kg/Week), March’2021
Figure 9-33: Kanjinti – Average Cost of Initial Week, Maintenance Week & Annual Treatment of Adjuvant Breast Cancer, Gastric Cancer & Esophageal Carcinoma (US$), March’2021
Figure 9-34: Herceptin Hylecta – Price for 5ml & Price Per ml of Subcutaneous Solution for Injection (US$), March’2021
Figure 9-35: Herceptin Hylecta – Duration of Single Treatment Cycle & Full Treatment (week), March’2021
Figure 9-36: Perjeta - Approval Year by Cancer Type
Figure 9-37: Perjeta – Patent Expiration Year by Region
Figure 9-38: Perjeta – Price for a Supply of 10 ml and Price Per ml of Intravenous Solution (US$), March’2021
Figure 9-39: Perjeta – Initial & Maintenance Dose for Breast Cancer Treatment (mg/3 weeks), March’2021
Figure 9-40: Perjeta – Minimum & Maximum Treatment Cost for Breast Cancer (US$), March’2021
Figure 9-41: Perjeta – Minimum & Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$), March’2021
Figure 9-42: US - Perjeta Annual Sales Value (US$/CHF Million), 2017 - 2020
Figure 9-43: US - Perjeta Quarterly Sales Value (US$ Billion), 2019
Figure 9-44: US - Perjeta Quarterly Sales Value (US$ Million), 2020
Figure 10-1: Avastin – FDA Approval Year by Indication
Figure 10-2: Avastin – Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$), March’2021
Figure 10-3: Avastin – Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$), March’2021
Figure 10-4: Avastin – Pice for Single Treatment Cycle & Annual Treatment of Breast Cancer (US$), March’2021
Figure 10-5: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), March’2021
Figure 10-6: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), March’2021
Figure 10-7: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks), March’2021
Figure 10-8: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), March’2021
Figure 10-9: US - Avastin Annual Sales Value (US$/CHF Billion), 2017 - 2020
Figure 10-10: US - Avastin Quarterly Sales Value (US$ Billion), 2019
Figure 10-11: US - Avastin Quarterly Sales Value (US$ Million), 2020
Figure 10-12: Mvasi - Price for 4ml Supply & Price Per ml of Intravenous Solution (US$), March’2021
Figure 10-13: Mvasi - Price for 16 ml Supply & Price Per Unit of Intravenous Solution (US$), March’2021
Figure 10-14: Mvasi – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), March’2021
Figure 10-15: Mvasi – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), March’2021
Figure 10-16: Global - Mvasi Annual Sales Value (US$ Million), 2019 & 2020
Figure 10-17: US - Mvasi Annual Sales Value (US$ Million), 2019 & 2020
Figure 10-18: Global - Mvasi Quarterly Sales Value (US$ Million), 2020
Figure 10-19: US - Mvasi Quarterly Sales Value (US$ Million), 2020
Figure 10-20: Zirabev - Price for 4ml Supply & Price Per Unit of Intravenous Solution (US$), March’2021
Figure 10-21: Zirabev - Price for 16 ml Supply & Price Per Unit of Intravenous Solution (US$), March’2021
Figure 10-22: Zirabev – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), March’2021
Figure 10-23: Zirabev – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), March’2021
Figure 10-24: US – Ramucirumab FDA Approval Year by Indication
Figure 10-25: US - Ramucirumab Patent Approval & Expiration Year
Figure 10-26: Cyramza – Cost of Supply of 10ml & Per Unit Cost of Intravenous Solution (US$), March’2021
Figure 10-27: Cyramza – Cost of Supply of 50ml & Per Unit Cost of Intravenous Solution (US$), March’2021
Figure 10-28: Cyramza – Cost of Single Cycle & Annual Treatment Cost for NSCLC (US$)
Figure 10-29: Cyramza – Cost of Single Cycle & Annual Treatment Cost for Gastric, Colorectal & Hepatocellular Carcinoma (US$)
Figure 10-30: Global – Cyramza Annual Sales (US$ Million), 2017-2020
Figure 10-31: US – Cyramza Annual Sales (US$ Million), 2017-2020
Figure 10-32: Cyramza – Annual Sales by Region (US$ Million), 2017-2020
Figure 10-33: Global - Cyramza Annual Sales Value by Region (%), 2020
Figure 10-34: Global – Cyramza Quarterly Sales (US$ Million), 2019 & 2020
Figure 11-1: Kadcyla – FDA Approval Year for Late Stage & Early Stage HER2+ Breast Cancer
Figure 11-2; Kadcyla – Price for Single Unit of 100mg & 160mg Intravenous Powder for Injection (US$), March’2021
Figure 11-3: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 11-4: Kadcyla – Average Cost of Single Treatment Cycle & Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US$), March’2021
Figure 11-5: Kadcyla – Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
Figure 11-6: US - Kadcyla Annual Sales Value (US$/CHF Million), 2017 - 2020
Figure 11-7: US - Kadcyla Quarterly Sales Value (US$ Billion), 2019
Figure 11-8: US - Kadcyla Quarterly Sales Value (US$ Million), 2020
Figure 11-9: Enhertu – FDA Approval Year for Late Stage & Early Stage HER2+ Breast Cancer
Figure 11-10: Enhertu – Cost of Single Supply & Single Treatment Cycle (US$), March’2021
Figure 11-11: Enhertu – Recommended Initial & Reduced Dose (mg/Kg/Cycle), March’2021
Figure 11-12: Enhertu – Cost of Single Treatment Cycle & Annual Treatment of Gastric Cancer (US$), March’2021
Figure 11-13: US - Enhertu Quarterly Sales Value (US$ Million), 2020
Figure 11-14: Trodelvy – FDA Approval & Patent Expiration Year
Figure 11-15: Trodelvy – Average Cost of Single Treatment Cycle & Full Treatment, March’2021
Figure 11-16: US - Trodelvy Quarterly Sales Value (US$ Million), Q2 – Q4, 2020
Figure 11-17: Lumoxiti – Year of Orphan Designation, FDA Approval & Patent Expiration
Figure 11-18: Lumoxiti – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 11-19: Lumoxitin – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), March’2021
Figure 11-20: Besponsa – Duration of Initial Treatment Cycle & Subsequent Cycles (Days)
Figure 11-21; Besponsa – Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m2)
Figure 11-22: Besponsa – Cost of Single Unit & Full Cost of Initial Treatment Cycle (US$), March’2021
Figure 11-23: Besponsa – Cost of Single Unit & Full Cost of Subsequent Treatment Cycle in Patient with CR (US$), March’2021
Figure 11-24: Besponsa – Duration of Treatment of ALL – After & Without HSCT (Weeks)
Figure 11-25: Mylotarg – FDA Approval, Withdrawal & Re-Approval Year
Figure 11-26: Mylotarg – Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
Figure 11-27: Mylotarg – Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), March’2021
Figure 11-28: Mylotarg – Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML
Figure 11-29: Mylotarg – Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)
Figure 11-30: Mylotarg – Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2)
Figure 11-31: Mylotarg – Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US$), March’2021
Figure 11-32: Mylotarg – Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, March’2021
Figure 11-33: Blenrep – Price for 100mg Supply & Price for Single Treatment Cycle (US$), March’2021
Figure 11-34: US - Blenrep Quarter Sales Value (US$/GBP Million), Q3 & Q4, 2020
Figure 11-35: Global - Blenrep Annual Sales Value by Region (US$/GBP Million), 2020
Figure 11-36: Blenrep - US v/s Rest of World Share in Sales Value (%), 2020
Figure 11-37: Adcetris – Patent Issue & Expiration Year
Figure 11-38: Adcetris – Maximum Cost for Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), March’2021
Figure 11-39: Adcetris – Duration for Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)
Figure 11-40: Global - Adcetris Sales Value (US$ Million), 2017 - 2020
Figure 11-41: Polivy – Patent Issue & Expiration Year
Figure 11-42: Polivy – Price for 30mg & 140mg Intravenous Powder for Injection (US$), March’2021
Figure 11-43: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks), March’2021
Figure 11-44: Polivy – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), March’2021
Figure 11-45: US - Polivy Annual Sales Value (US$/CHF Million), 2019 & 2020
Figure 11-46: US - Polivy Quarter Sales Value (US$/CHF Million), Q3 & Q4, 2019
Figure 11-47: US - Polivy Quarter Sales Value (US$/CHF Million), 2020
Figure 11-48: Polivy - US v/s Rest of World Share in Sales Value (%), 2020
Figure 11-49: Padcev – Price for 20mg & 30mg Intravenous Powder for Injection (US$), March’2021
Figure 11-50: Padcev – Average Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), March’2021
Figure 11-51: US - Padcev Annual Sales Value (US$ Million), 2019 - 2020
Figure 11-52: US - Padcev Quarterly Sales Value (US$ Million), 2020
Figure 12-1: Rituxan – FDA Approval Year by Indication
Figure 12-2: Rituxan – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 12-3: Rituxan – Price for a Supply of 50 ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 12-4: Rituxan – Price for a Supply of 100 ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 12-5: Rituxan – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), March’2021
Figure 12-6: Rituxan – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), March’2021
Figure 12-7: US - Rituxan Annual Sales Value (US$/CHF Billion), 2017 - 2020
Figure 12-8: US - Rituxan Quarterly Sales Value (US$ Billion), 2019
Figure 12-9: US - Rituxan Quarterly Sales Value (US$ Million), 2020
Figure 12-10: Rituxan – Annual Sales Value by Region (%), 2020
Figure 12-11: Truxima – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 12-12: Truxima – Price for a Supply of 50 ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 12-13: Truxima – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), March’2021
Figure 12-14: Truxima – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), March’2021
Figure 12-15: Riabni – Cost of Supply of 10ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), March’2021
Figure 12-16: Riabni – Cost of Supply of 50ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), March’2021
Figure 12-17: Riabni – Cost of 8 Cycles, 4 Cycles & Single Cycle for Management of NHL (US$)
Figure 12-18: Ruxience – Cost of Supply of 10ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), March’2021
Figure 12-19: Ruxience – Cost of Supply of 50ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), March’2021
Figure 12-20: Ruxience – Cost of 8 Cycles, 4 Cycles & Single Cycle for Management of NHL (US$)
Figure 12-21: Rituxan Hycela – Price for 11.7 ml Supply & Price Per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US$), March’2021
Figure 12-22: Rituxan Hycela – Price for 13.4 ml Supply & Price Per ml of 26,800 units–1,600 mg/13.4ml Subcutaneous Solution (US$), March’2021
Figure 12-23: Rituxan Hycela –Minimum & Maximum Duration of Follicular lymphoma Treatment (Weeks)
Figure 12-24: Rituxan Hycela – Average Minimum & Maximum Cost of Follicular lymphoma (US$), March’2021
Figure 12-25: Rituxan Hycela – Duration of Single Treatment Cycle & Full Treatment of Previously Untreated Follicular lymphoma (US$)
Figure 12-26: Rituxan Hycela – Average Minimum & Maximum Cost of Previously Untreated Follicular lymphoma (US$), March’2021
Figure 12-27: Rituxan Hycela – Average Minimum & Maximum Cost of Diffuse Large B-Cell Lymphoma (US$), March’2021
Figure 12-28: Rituxan Hycela – Duration of CLL Treatment (Weeks)
Figure 12-29: Rituxan Hycela - Cost of Single Treatment Cycle & Full Treatment of CLL (US$), March’2021
Figure 12-30: Gazyva – Approval Year by Cancer Type
Figure 12-31: Gazyva – Price for 40ml Supply & Price Per ml of Intravenous Solution (US$), March’2021
Figure 12-32: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg), March’2021
Figure 12-33: Gazyva – Duration of Single Treatment Cycle & Full Treatment of CLL (Week), March’2021
Figure 12-34: Gazyva – Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US$), March’2021
Figure 12-35: Gazyva – Minimum & Maximum Duration for Follicular Lymphoma Treatment (Week), March’2021
Figure 12-36: Gazyva – Minimum & Maximum Treatment Cost of Follicular Lymphoma (US$), March’2021
Figure 12-37: Gazyva – Duration of Single Treatment Cycle & Full Treatment Using Monotherapy (Months), March’2021
Figure 12-38: Gazyva – Cost of Single Treatment Cycle & Full Treatment using Monotherapy (US$), March’2021
Figure 12-39: Gazyva – Annual Sales Value (US$/CHF Million), 2017 - 2020
Figure 12-40: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2019
Figure 12-41: Gazyva - US v/s Rest of World Share in Sales Value (%), 2019
Figure 12-42: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2020
Figure 12-43: Gazyva - US v/s Rest of World Share in Sales Value (%), 2020
Figure 12-44: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), March’2021
Figure 12-45: Arzerra – Price for a Supply of 50 ml & Price Per ml of Intravenous Solution (US$), March’2021
Figure 12-46: Arzerra – Initial & Maintenance Dose for Previously Untreated CLL (mg), March’2021
Figure 12-47: Arzerra – Minimum & Maximum Treatment Duration for Previously Untreated CLL (Weeks), March’2021
Figure 12-48: Arzerra – Minimum & Maximum Treatment Cost for Previously Untreated CLL (US$), March’2021
Figure 12-49: Arzerra – Initial & Maintenance Dose for Relapsed CLL (mg), March’2021
Figure 12-50: Arzerra – Minimum & Maximum Treatment Cost for Relapsed CLL (US$), March’2021
Figure 12-51: Arzerra – Initial & Maintenance Dose for Refractory CLL (mg), March’2021
Figure 12-52: Arzerra – Treatment Duration for Refractory CLL (Weeks), March’2021
Figure 12-53: Arzerra – Minimum & Maximum Treatment Cost for Refractory CLL (US$), March’2021
Figure 13-1: Blincyto - Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, March’2021
Figure 13-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , March’2021
Figure 13-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US$), March’2021
Figure 13-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, March’2021
Figure 13-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), March’2021
Figure 13-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), March’2021
Figure 13-7: Blincyto - Cost of Different Treatment Phases for Relapsed B-Cell Precursor ALL (US$), March’2021
Figure 13-8: US - Blincyto Sales Value (US$ Million), 2016 - 2020
Figure 13-9: Blincyto - Quarterly Sales Value (US$ Million), 2019
Figure 13-10: Blincyto - US v/s Rest of World Share in Sales Value (%), 2019
Figure 13-11: US - Blincyto Quarterly Sales Value (US$ Million), 2020
Figure 13-12: Blincyto - US v/s Rest of World Share in Sales Value (%), 2020
Figure 14-1: Lemtrada – Price for 1.2ml Supply & Price Per ml of Intravenous Solution (US$), March’2021
Figure 14-2: Lemtrada – Cost of Single Dose & Single Treatment Cycle (US$), March’2021
Figure 14-3: US - Lemtrada Annual Sales Value (US$/EUR Million), 2018 - 2020
Figure 14-4: US - Lemtrada Quarterly Sales Value (US$/EUR Million), 2020
Figure 14-5: Lemtrada - US v/s Rest of World Share in Sales Value (%), 2020
Figure 15-1: Sarclisa – FDA Approval & Patent Expiration Year
Figure 15-2: Sarclisa – Price for 5 ml Supply & Price Per ml of 20mg/ml Intravenous Solution (US$), March’2021
Figure 15-3: Sarclisa – Price for 25 ml Supply & Price Per ml of 20mg/ml Intravenous Solution (US$), March’2021
Figure 15-4: Sarclisa – Number of Dose Required in Initial & Subsequent Treatment Cycles (Weeks)
Figure 15-5: US - Sarclisa Quarter Sales Value (US$/EUR Million), 2020
Figure 15-6: Global - Sarclisa Annual Sales Value by Region (US$/EUR Million), 2020
Figure 15-7: Sarclisa - US v/s Rest of World Share in Sales Value (%), 2020
Figure 15-8: Darzalex – FDA Approval & Patent Expiration Year
Figure 15-9: Darzalex – Price for 5 ml Supply & Price Per ml of 20mg/ml Intravenous Solution (US$), March’2021
Figure 15-10: Darzalex – Price for 20 ml Supply & Price Per ml of 20mg/ml Intravenous Solution (US$), March’2021
Figure 15-11: Darzalex – Duration of Dose Interval by Treatment Phase (Weeks)
Figure 15-12: US - Darzalex Annual Sales Value (US$ Million), 2017 - 2020
Figure 15-13: Darzalex – Annual Sales by Region (%), 2019
Figure 15-14: US - Darzalex Quarterly Sales Value (US$ Million), 2019
Figure 15-15: US - Darzalex Quarterly Sales Value (US$ Million), 2020
Figure 15-16: Darzalex – Annual Sales by Region (%), 2020
Figure 15-17: Darzalex Faspro – FDA Approval & Patent Expiration Year
Figure 15-18: Darzalex Faspro – Price for 15 ml Supply & Price Per ml of Subcutaneous Solution (US$), March’2021
Figure 15-19: Darzalex Faspro – Duration of Dose Interval by Treatment Phase (Weeks)
Figure 16-1: Keytruda – Patent Expiration Year by Region
Figure 16-2: Keytruda – Price for 4ml & 8ml Supply & Price Per ml of Intravenous Injection (US$), March’2021
Figure 16-3: Keytruda – Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks), March’2021
Figure 16-4: Keytruda - Cost of Single & Full Treatment using Solution of Injection (US$), March’2021
Figure 16-5: Global - Keytruda Annual Sales Value by Region (US$ Billion), 2020
Figure 16-6: Global - Keytruda Annual Sales Value by Region (%), 2020
Figure 16-7: US - Keytruda Annual Sales Value (US$ Billion), 2017 - 2020
Figure 16-8: US - Keytruda Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 16-9: US - Keytruda Quarterly Sales Value (US$ Million), 2020
Figure 16-10: Yervoy – US & Europe Exclusivity Expiration Year
Figure 16-11: Yervoy - Price for 10ml Supply & Price Per ml 5mg/ml Intravenous Injection (US$), March’2021
Figure 16-12: Yervoy – Price for 40ml Supply & Price Per ml 5mg/ml Intravenous Injection (US$), March’2021
Figure 16-13: Yervoy – Duration of Single Treatment Cycle & Full Treatment of Metastatic Melanoma & Hepatocellular Carcinoma (Weeks), March’2021
Figure 16-14: Yervoy – Average Cost of Single Treatment Cycle & Full Treatment of Metastatic Melanoma & Hepatocellular Carcinoma (US$), March’2021
Figure 16-15: Yervoy – Average Cost of Single Treatment Cycle, Initial Year & Remaining Years for Management of Metastatic Melanoma (US$), March’2021
Figure 16-16: Yervoy – Annual Sales Value (US$ Billion), 2016-2020
Figure 16-17: Global - Yervoy Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 16-18: US - Yervoy Quarterly Sales Value (US$ Million), Q1-Q4, 2019
Figure 16-19: Yervoy – US v/s Rest of World Sales Share (%), 2019
Figure 16-20: Global - Yervoy Quarterly Sales Value (US$ Million), Q1-Q4, 2020
Figure 16-21: US - Yervoy Quarterly Sales Value (US$ Million), Q1-Q4, 2020
Figure 16-22: Yervoy – Annual Sales by Region (%), 2020
Figure 16-23: Opdivo – FDA Approval by Indication
Figure 16-24: Opdivo - Patent Expiration Year by Region
Figure 16-25: Opdivo - Price for 4ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), March’2021
Figure 16-26: Opdivo - Price for 10 ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), March’2021
Figure 16-27: Opdivo - Price for 20 ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), March’2021
Figure 16-28: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), March’2021
Figure 16-29: US - Opdivo Annual Sales Value (US$ Million), 2016 - 2020
Figure 16-30: Opdivo – Annual Sales by Region (%), 2019
Figure 16-31: US - Opdivo Quarterly Sales Value (US$ Billion), 2018 & 2019
Figure 16-32: US - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 16-33: Imfinzi – FDA Approval Year by Indication
Figure 16-34: Imfinzi – FDA Approval & Patent Expiration Year
Figure 16-35: Imfinzi – Price for a Supply of 2.4ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 16-36: Imfinzi – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 16-37: Imfinzi - Average Cost of Single Treatment Cycle & Full Treatment of NSCLC (US$), March’2021
Figure 16-38: Global - Imfinzi Annual Sales Value (US$ Million), 2017 - 2020
Figure 16-39: US - Imfinzi Annual Sales Value (US$ Million), 2017 - 2020
Figure 16-40: Imfinzi - Quarterly Sales Value by Region (US$ Million), 2018 & 2019
Figure 16-41: Global - Imfinzi Quarterly Sales Value (US$ Million), 2020
Figure 16-42: US - Imfinzi Quarterly Sales Value US$ Million), 2020
Figure 16-43: Imfinzi – Annual Sales by Region (%), 2020
Figure 16-44: Bavencio – FDA Approval Year by Indication
Figure 16-45: Bavencio - Price for 10ml Supply & Price Per ml of 20mg/ml Intravenous Injection (US$), March’2021
Figure 16-46: Bavencio - Average Cost of Single Treatment Cycle & Annual Treatment (US$), March’2021
Figure 16-47: Bavencio – Annual Sales Value (US$/EUR Million), 2017-2019
Figure 16-48: Bavencio – Quarterly Sales Value (US$ Million), Q1-Q3, 2019 & 2020
Figure 16-49: Tecentriq – FDA Approval Year by Indication
Figure 16-50: Tecentriq - Price for 14ml Supply & Price Per ml of 840mg/14ml Intravenous Injection (US$), March’2021
Figure 16-51: Tecentriq - Price for 20ml Supply & Price Per ml of 1200mg/20ml Intravenous Injection (US$), March’2021
Figure 16-52: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 840mg/2 Week Dose (US$), March’2021
Figure 16-53: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1200mg/3 Week Dose (US$), March’2021
Figure 16-54: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1680mg/4 Week Dose (US$), March’2021
Figure 16-55: US - Tecentriq Annual Sales Value (US$/CHF Million), 2018 - 2020
Figure 16-56: US - Tecentriq Quarterly Sales Value (US$ Million), 2019
Figure 16-57: US - Tecentriq Quarterly Sales Value (US$ Million), 2020
Figure 16-58: Libtayo – FDA Approval Year by Indication
Figure 16-59: Libtayo – Price for a Supply of 7ml & Price Per ml of Solution for Injection (US$), March’2021
Figure 16-60: Libtayo – Cost of Single Treatment Cycle & Annual Treatment Cost (US$), March’2021
Figure 16-61: Global Libtayo Quarterly Sales Value (US$ Million), 2019
Figure 16-62: US - Libtayo Quarterly Sales Value (US$ Million), 2019
Figure 16-63: Libtayo – Annual Sales by Region (%), 2019
Figure 16-64: Libtayo – Quarterly Sales Value (US$ Million), 2020
Figure 16-65: US - Libtayo Quarterly Sales Value (US$ Million), 2020
Figure 16-66: Libtayo – Annual Sales by Region (%), 2020
Figure 17-1: Erbitux - Approval Year by Cancer Type
Figure 17-2: Erbitux - Price for a Supply of 50 ml & Per unit Price of Intravenous Solution (US$), March’2021
Figure 17-3: Erbitux - Price for a Supply of 100 ml & Per unit Price of Intravenous Solution (US$), March’2021
Figure 17-4: Cetuximab – Initial & Maintenance Dose for Colorectal Cancer & Head and Neck Cancer (mg/ m2)
Figure 17-5: Cetuximab – Recommended Dose & Reduced Dose (mg/ m2)
Figure 17-6: Global – Erbitux Annual Sales (US$ Million), 2017-2019
Figure 17-7: Cetuximab - Annual Sales by Region (US$ Million), 2018 & 2019
Figure 17-8: Cetuximab - Annual Sales by Region (%), 2019
Figure 17-9: US – Necitumumab FDA Approval & Patent Exclusivity Year
Figure 17-10: Portrazza - Price for 50ml Supply & Price per unit of 16mg Intravenous Solution (US$), March’2021
Figure 17-11: Portrazza – Minimum Dose & Maximum Dose (in mg)
Figure 17-12: Vectibix - FDA Approval & Patent Expiration Year
Figure 17-13: Vectibix – Price for a Supply of 5 ml & Price Per ml of Intravenous Solution (US$), March’2021
Figure 17-14: Vectibix – Price for a Supply of 20 ml & Price Per ml of Intravenous Solution (US$), March’2021
Figure 17-15: Vectibix – Cost of Single Treatment Cycle & Annual Treatment Cost for Colorectal Cancer (US$), March’2021
Figure 17-16: Global - Vectibix Annual Sales Value (US$ Million), 2015 - 2020
Figure 17-17: US - Vectibix Annual Sales Value (US$ Million), 2018 - 2020
Figure 17-18: Vectibix - Sales Share US v/s Rest of World (%), 2019
Figure 17-19: Global – Vectibix Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 17-20: Vectibix – Quarterly Sales Value by Region (US$ Million), 2020
Figure 17-21: Vectibix – Annual Sales Value (%) by Region, 2020
Figure 18-1: Phesgo – Price for various Supplies of Subcutaneous Solution for Injection (US$), March’2021
Figure 18-2: Phesgo – Duration of Treatment by Type (Cycles), March’2021
Figure 19-1: ELZONRIS – Average Cost for Single Treatment Cycle & Annual Treatment Cost (US$), March’2021
Figure 19-2: US - Elzonris Quarterly Sales Value (US$ Million), 2019
Figure 19-3: Monjuvi – Number of Dose per Treatment Cycle by Phase
Figure 19-4: Monjuvi – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 19-5: Monjuvi – Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), March’2021
Figure 19-6: US - Monjuvi Quarterly Sales Value (US$ Million), Q3 & Q4, 2020
Figure 19-7: Poteligeo – FDA Approval & Patent Expiration Year
Figure 19-8: Poteligeo – Price for 5ml Supply & Price Per Unit of 4mg/l Intravenous Solution (US$), March’2021
Figure 19-9: Poteligeo – Number of Dose Administration in Initial & Subsequent Treatment Cycle
Figure 19-10: Poteligeo – Cost of Single Dose, Initial & Subsequent Treatment Cycle (US$), March’2021
Figure 19-11: Global - Poteligeo Sales Value (US$ Million), 2018 - 2020
Figure 19-12: Xgeva – Cost of Supply of 1.7ml & Per Unit Price of 120mg Solution (US$), March’2021
Figure 19-13: Xgeva – Cost of Single Cycle & Annual Cost of Treatment in Multiple Myeloma (US$)
Figure 19-14: Global – Xgeva Annual Sales (US$ Million), 2017-2020
Figure 19-15: Xgeva - Annual Sales by Region (US$ Million), 2019
Figure 19-16: Xgeva - Annual Sales by Region (%), 2019
Figure 19-17: Xgeva - Quarterely Sales by Region (US$ Million), 2019
Figure 19-18: Global – Xgeva Quarterely Sales (US$ Million), 2020
Figure 19-19: US – Xgeva Quarterely Sales (US$ Million), 2020
Figure 19-20: Xgeva - Annual Sales by Region (%), 2020
Figure 19-21: Empliciti – Patent Issue & Expiration Year
Figure 19-22: Empliciti – Price for 300mg & 400mg Supply of Intravenous Powder for Injection (US$), March’2021
Figure 19-23: Empliciti – Number of Dose Administration During Initial 2 Cycles & Subsequent Cycles
Figure 19-24: Empliciti – Cost of Single Cycle During Initial 2 Cycles & Subsequent Cycles (US$), March’2021
Figure 19-25: US - Empliciti Annual Sales Value (US$ Million), 2017 - 2020
Figure 19-26: Empliciti – Annual Sales by Region (%), 2019
Figure 19-27: US - Empliciti Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 19-28: US - Empliciti Quarterly Sales Value (US$ Million), 2020
Figure 19-29: Empliciti – Annual Sales by Region (%), 2020
Figure 19-30: US – Unituxin FDA Approval & Patent Exclusivity Year
Figure 19-31: Unituxin – Cost of Supply of 5ml & Per Unit Cost of Intravenous Solution (US$), March’2021
Figure 19-32: Unituxin – Cost of Single Cycle & Full Treatment Cost (US$)
Figure 19-33: Global – Unituxin Annual Sales (US$ Million), 2017-2020
Figure 19-34: Global – Unituxin Quarterely Sales (US$ Million), 2020
Figure 19-35: Naxitamab – Cost of Supply of 10ml & Per Unit Cost of Intravenous Solution (US$), March’2021
